ALLO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Given the user's long-term investment strategy and beginner level, Allogene Therapeutics Inc (ALLO) is not a strong buy at this time. While there are positive catalysts such as promising trial data and analyst optimism, the company's weak financial performance, lack of proprietary trading signals, and technical indicators suggesting potential short-term downside make it prudent to hold off on investing for now.
The stock's MACD is negatively expanding, indicating bearish momentum. RSI is neutral at 44.327, offering no clear signal. While moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the stock is trading below key pivot levels, with resistance at $2.967 and support at $1.97.
Strong interim data from the ALPHA3 trial showing significant MRD clearance improvements.
Analysts have raised price targets significantly, with multiple firms maintaining Buy or Outperform ratings.
Recent $175M public offering bolsters the company's financial resources for R&D and clinical trials.
Weak financial performance in Q4 2025, with revenue at $0 and net income dropping 35.25% YoY.
Stock trend analysis indicates a 60% chance of short-term price declines.
Lack of significant insider or hedge fund trading activity, suggesting neutral sentiment.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -$38.81M (-35.25% YoY), and a declining EPS of -0.17 (-39.29% YoY). Gross margin was 0, reflecting no profitability.
Analysts are optimistic, with multiple firms upgrading price targets and maintaining Buy ratings. JPMorgan upgraded the stock to Neutral citing valuation, while Jefferies, H.C. Wainwright, and others highlight significant upside potential due to strong trial data. Price targets range from $3.85 to $12, reflecting varied confidence levels.
